Compare ARWR & GMED Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARWR | GMED |
|---|---|---|
| Founded | 2003 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.4B | 11.0B |
| IPO Year | 2009 | 2012 |
| Metric | ARWR | GMED |
|---|---|---|
| Price | $61.29 | $73.55 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 14 | 15 |
| Target Price | ★ $107.23 | $100.92 |
| AVG Volume (30 Days) | ★ 2.1M | 1.5M |
| Earning Date | 11-24-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 99.80 | ★ 422.67 |
| EPS | N/A | ★ 2.00 |
| Revenue | $16,142,321.00 | ★ $2,938,931,000.00 |
| Revenue This Year | N/A | $8.87 |
| Revenue Next Year | N/A | $6.04 |
| P/E Ratio | ★ N/A | $38.15 |
| Revenue Growth | N/A | ★ 16.65 |
| 52 Week Low | $34.61 | $56.52 |
| 52 Week High | $95.49 | $101.40 |
| Indicator | ARWR | GMED |
|---|---|---|
| Relative Strength Index (RSI) | 26.63 | 39.47 |
| Support Level | $60.87 | N/A |
| Resistance Level | $66.37 | $82.23 |
| Average True Range (ATR) | 2.53 | 1.65 |
| MACD | -0.36 | 0.31 |
| Stochastic Oscillator | 6.54 | 8.92 |
Arrowhead Pharmaceuticals Inc is a commercial-stage pharmaceutical company. It is focused on the development of medicines for diseases associated with genetic abnormalities or protein overproduction. The company develops potential RNAi therapies designed to inhibit the expression of genes known to trigger diseases. Its portfolio includes potential drugs targeting Cardiometabolic, Neuromuscular, Pulmonary, Liver, and other diseases. The company also develops RNAi products and clinical candidates designed to target different cell types within the body.
Globus Medical Inc is a medical device company that develops and provides healthcare products and solutions to hospitals, physicians, and surgical centers. The firm's products are organized into two categories: musculoskeletal solutions, which include medical devices and instruments used mostly for spinal and orthopedic procedures, and enabling technologies, which include computer systems developed for enhancing surgical capabilities. The vast majority of the company's revenue is generated from musculoskeletal solutions products, and more than half of the revenue is earned in the United States. It also has its presence internationally.